
BiolInvent Q3 2024 - New Positive BI-1206 SC Data

Redeye comments on BiolInvent's Q3 report, which presented new data for the subcutaneous version of BI-1206 in combination with rituximab in lymphoma.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[BiolInvent Q3 2024 - New Positive BI-1206 SC Data](#)